We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+2.49%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$280M
AUM Growth
-$281M
Cap. Flow
-$284M
Cap. Flow %
-101.42%
Top 10 Hldgs %
74.06%
Holding
63
New
4
Increased
2
Reduced
14
Closed
32

Top Buys

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$1.74M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$1.58M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$377K
4
AMRN
Amarin Corp
AMRN
+$268K
5
CHRS icon
Coherus Oncology
CHRS
+$151K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$63.8M
2
ARGX icon
argenx
ARGX
+$30.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.6M
4
VCYT icon
Veracyte
VCYT
+$17.3M
5
ASND icon
Ascendis Pharma A/S
ASND
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CUTR
51
DELISTED
Cutera, Inc.
CUTR
– –
-105,000
Closed -$4.23M
ASXC
52
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-1,923
Closed -$109K
ZYNE
53
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-50,000
Closed -$487K
OBSV
54
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-424,300
Closed -$6.42M
VIVE
55
DELISTED
VIVEVE MED INC
VIVE
– –
-268
Closed -$728K
AERI
56
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-61,000
Closed -$4.12M
PTE
57
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-1,000
Closed -$589K
FTSV
58
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-73,000
Closed -$1.17M
TSRO
59
DELISTED
TESARO, Inc.
TSRO
– –
-50,000
Closed -$2.22M
ZGNX
60
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-82,500
Closed -$3.65M
ZGNX
61
DELISTED
Zogenix, Inc.
ZGNX
– –
-110,500
Closed -$4.88M
ZGNX
62
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-45,000
Closed -$1.99M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Acuta Capital Partners held 63 positions worth $280M, down 50% from $562M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Acuta Capital Partners withdrew a net $284M in Q3 2018, closing 32 positions and reducing 14 holdings. Its most notable exit was Indaptus Therapeutics, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 68% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in KalVista Pharmaceuticals worth $2.85M.

  • Acuta Capital Partners's largest Q3 2018 buy was KalVista Pharmaceuticals: 128,844 shares worth $2.85M.
  • Acuta Capital Partners added most to Xenon Pharmaceuticals in Q3 2018, an estimated $377K increase.
  • Acuta Capital Partners's biggest Q3 2018 reduction was Immunomedics Inc, cutting an estimated $63.8M.
  • Acuta Capital Partners fully exited Indaptus Therapeutics in Q3 2018, selling an estimated $13M.
  • Acuta Capital Partners's ten largest holdings make up 74% of its $280M portfolio in Q3 2018.
  • Acuta Capital Partners opened 4 new positions and closed 32 in Q3 2018.
  • Acuta Capital Partners's portfolio value fell 50% quarter-over-quarter to $280M.

Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.